Boston Scientific’s (NYSE:BSX) Lotus transcatheter aortic valve implantation system fared well in an early feasibility study in patients with severe symptomatic aortic stenosis who were to sick to undergo open-heart surgery.
Replacement Heart Valves
MassDevice.com +7 | The top 7 med-tech stories for the week of April 30, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Edwards wins CMS Medicare coverage for Sapien TAVI system
Shares of Edwards Lifesciences (NYSE:EW) jumped a few points as the Centers for Medicare & Medicaid affirmed coverage for the med-tech titan’s landmark Sapien transcatheter aortic valve implantation system.
EW shares jumped 2.2% to $84.78 in after hours trading as of about 6 p.m. today.
MassDevice.com +3 | The top 3 med-tech stories for April 25, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Edwards’ Sapien sales spike 67% during 1st quarter on U.S. market
Shares of Edwards Lifesciences (NYSE:EW) got a little boost on Wall Street after the company posted a 67% spike in Sapien sales during its 1st quarter.
The Irvine, Calif.-based med-tech titan posted $459.2 million in sales during the 3 months ended March 31, a 13.5% increase from he $404.5 million in revenues posted during the same period last year.
Diabetes: NeuroMetrix touts weight loss study at Joslin Diabetes Center | MassDevice.com On Call
MASSDEVICE ON CALL — Waltham, Mass.-based NeuroMetrix (NSDQ:NURO) announced its support of the Joslin Diabetes Center’s "Why Wait" program targeting obese patients with diabetes.
FDA looks to strengthen device surveillance post-Riata | MassDevice.com On Call
MASSDEVICE ON CALL — Under increasing pressure from doctors, the FDA this month will unveil a new medical device post-market surveillance program aimed at better tracking potentially faulty devices.
The more rigorous program will include unique device identifiers that allow the FDA, doctors and manufacturers to track individual devices and better monitor, track and report defects.
MassDevice.com +3 | The top 3 med-tech stories for April 9, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Sapien heart valve gets FDA date for Edwards Lifesciences
Edwards Lifesciences (NYSE:EW) said the FDA set a date for its circulatory devices advisory panel to review a pre-market approval application for its Sapien heart valve.
ACC 2012: Headlines from this week’s American College of Cardiology conference
ACC 2012: Bypass surgery beats PCI at 4 years | MassDevice.com On Call
MASSDEVICE ON CALL — Coronary artery bypass surgery beat out percutaneous stenting for mortality rates after 4 years in a large observational study of nearly 200,000 patients aged 65 and older, according to a new study unveiled at this week’s American College of Cardiology conference in Chicago.
The analysis was adjusted to control for factors such as age, sex, diabetes, renal function and lung disease, and researchers concluded that CABG patients lived longer, "even among patients whose propensity scores were most consistent with selection for PCI."